New drug development in head and neck squamous cell carcinoma: The PI3-K inhibitors

被引：19

作者：

De Felice, Francesca ^{[1
]}

Urbano, Teresa Guerrero ^{[2
]}

机构：

[1] Sapienza Univ Rome, Policlin Umberto 1, Dept Radiotherapy, Viale Regina Elena 326, I-00161 Rome, Italy

[2] Guys & St Thomas NHS Fdn Trust, Dept Clin Oncol, London, England

来源：

ORAL ONCOLOGY | 2017年 / 67卷

关键词：

PI3-K inhibitors; Radiotherapy; Head and neck cancer; Squamous cell; Locally advanced disease; Recurrence; Survival; MULTICENTER PHASE-1; CANCER; CETUXIMAB; PATHWAY; PX-866; RADIORESISTANCE; PI3K-C2-ALPHA; SURVIVAL;

D O I：

10.1016/j.oraloncology.2017.02.020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Over the last few years a number of new different compounds have been developed. They include phosphatidylinositol 3-kinase (PI3-K) inhibitors. Deregulation within the PI3-K pathway is common in head neck squamous cell carcinoma (HNSCC) and it represents a growing area of research. PI3-K inhibitors, including BKM120, PX-866 and BYL719, are being tested in several phase I and phase II studies in patients with locally advanced, recurrent or metastatic disease. This review provides an update of published clinical trials and highlights the challenges of PI3-K inhibitors in HNSCC. (C) 2017 Elsevier Ltd. All rights reserved.

引用

页码：119 / 123

页数：5

共 28 条

[1]

[Anonymous], J CLIN ONCOL

[2] The regulation and function of Class III PI3Ks: novel roles for Vps34 [J].

Backer, Jonathan M. .

BIOCHEMICAL JOURNAL, 2008, 410 (01) :1-17

[3] A specific function for phosphatidylinositol 3-kinase α (p85α-p110α) in cell survival and for phosphatidylinositol 3-kinase β (p85α-p110β) in de novo DNA synthesis of human colon carcinoma cells [J].

Bénistant, C ;

Chapuis, H ;

Roche, S .

ONCOGENE, 2000, 19 (44) :5083-5090

[4] A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours [J].

Bowles, D. W. ;

Ma, W. W. ;

Senzer, N. ;

Brahmer, J. R. ;

Adjei, A. A. ;

Davies, M. ;

Lazar, A. J. ;

Vo, A. ;

Peterson, S. ;

Walker, L. ;

Hausman, D. ;

Rudin, C. M. ;

Jimeno, A. .

BRITISH JOURNAL OF CANCER, 2013, 109 (05) :1085-1092

[5] A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck [J].

Bowles, Daniel W. ;

Senzer, Neil ;

Hausman, Diana ;

Peterson, Scott ;

Vo, Alex ;

Walker, Luke ;

Cohen, Roger B. ;

Jimeno, Antonio .

INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) :1197-1203

[6] PI3K-C2α: One enzyme for two products coupling vesicle trafficking and signal transduction [J].

Campa, Carlo C. ;

Franco, Irene ;

Hirsch, Emilio .

FEBS LETTERS, 2015, 589 (14) :1552-1558

[7] Cancer-Specific High-Throughput Annotation of Somatic Mutations: Computational Prediction of Driver Missense Mutations [J].

Carter, Hannah ;

Chen, Sining ;

Isik, Leyla ;

Tyekucheva, Svitlana ;

Velculescu, Victor E. ;

Kinzler, Kenneth W. ;

Vogelstein, Bert ;

Karchin, Rachel .

CANCER RESEARCH, 2009, 69 (16) :6660-6667

[8] PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways [J].

Chang, L. ;

Graham, P. H. ;

Hao, J. ;

Ni, J. ;

Bucci, J. ;

Cozzi, P. J. ;

Kearsley, J. H. ;

Li, Y. .

CELL DEATH & DISEASE, 2014, 5 :e1437-e1437

[9] Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing [J].

Chung, C. H. ;

Guthrie, V. B. ;

Masica, D. L. ;

Tokheim, C. ;

Kang, H. ;

Richmon, J. ;

Agrawal, N. ;

Fakhry, C. ;

Quon, H. ;

Subramaniam, R. M. ;

Zuo, Z. ;

Seiwert, T. ;

Chalmers, Z. R. ;

Frampton, G. M. ;

Ali, S. M. ;

Yelensky, R. ;

Stephens, P. J. ;

Miller, V. A. ;

Karchin, R. ;

Bishop, J. A. .

ANNALS OF ONCOLOGY, 2015, 26 (06) :1216-1223

[10] The phosphoinositide (PI) 3-kinase family [J].

Foster, FM ;

Traer, CJ ;

Abraham, SM ;

Fry, MJ .

JOURNAL OF CELL SCIENCE, 2003, 116 (15) :3037-3040

← 1 2 3 →